Solid Tumour Target Discovery Group, Northern Institute for Cancer Research, Newcastle University, Paul O'Gorman Building, Newcastle Upon Tyne, NE2 4HH, UK.
Nucleic Acids Res. 2011 Mar;39(4):1266-79. doi: 10.1093/nar/gkq861. Epub 2010 Oct 19.
The androgen receptor (AR) is a member of the nuclear hormone receptor family of transcription factors that plays a critical role in regulating expression of genes involved in prostate development and transformation. Upon hormone binding, the AR associates with numerous co-regulator proteins that regulate the activation status of target genes via flux to the post-translational modification status of histones and the receptor. Here we show that the AR interacts with and is directly methylated by the histone methyltransferase enzyme SET9. Methylation of the AR on lysine 632 is necessary for enhancing transcriptional activity of the receptor by facilitating both inter-domain communication between the N- and C-termini and recruitment to androgen-target genes. We also show that SET9 is pro-proliferative and anti-apoptotic in prostate cancer cells and demonstrates up-regulated nuclear expression in prostate cancer tissue. In all, our date indicate a new mechanism of AR regulation that may be therapeutically exploitable for prostate cancer treatment.
雄激素受体(AR)是核激素受体转录因子家族的一员,在调节参与前列腺发育和转化的基因表达方面起着关键作用。激素结合后,AR 与许多共调节蛋白结合,通过向组蛋白和受体的翻译后修饰状态的通量来调节靶基因的激活状态。在这里,我们表明 AR 与组蛋白甲基转移酶酶 SET9 相互作用并直接被其甲基化。AR 赖氨酸 632 上的甲基化对于增强受体的转录活性是必需的,因为它促进了 N-和 C-末端之间的结构域间通讯,并募集到雄激素靶基因。我们还表明,SET9 在前列腺癌细胞中具有促增殖和抗凋亡作用,并在前列腺癌组织中表现出上调的核表达。总之,我们的数据表明了 AR 调节的一种新机制,这可能在前列腺癌治疗中具有治疗潜力。